BMS-564929 is an investigational selective androgen receptor modulator which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men (andropause). These symptoms may include depression loss of muscle mass and strength reduction in libido and osteoporosis.
This page contains content from the copyrighted Wikipedia article "BMS-564929"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
